Pillstats
Rx only · Injection, Suspension · Subcutaneous

Insulin Aspart

Brands: .Insulin Aspart Protamine And Insulin Aspart · Novolog Mix 70/30 · Insulin Aspart

3 ACTIVE SUPPLIERS — US
openFDA · updated weekly
US10 NDCs
3 active makers
UKComing
soon
CAComing
soon
AUComing
soon
EUComing
soon
RxCUI (US)51428
US makers3 labelers
Packages10
DEA / ScheduleNone

US acquisition costNADAC · per unit

Average across 4 priced NDCs. A benchmark of pharmacy acquisition cost — not a retail quote.

$2.29$4.57$6.86$9.14Dec 2025Apr 2026Jul 2026
$7.940
Latest avg · Jul 22, 2026
-0%
Since Dec 17, 2025
3
Active US suppliers
80%
Top-2 supplier share*

Medicaid dispensing volumeSDUD · per quarter

Prescriptions dispensed under Medicaid (fee-for-service + managed care), summed nationally. The closest free proxy to sales volume — Medicaid only, not all-payer.

8.5K17K25K34K2025 Q12025 Q22025 Q32025 Q42026 Q1
20K
Rx · 2026 Q1
458K
Units dispensed
-31%
Rx vs. year ago
5
Quarters · since 2025 Q1

Who makes it3 active · 0 exited

US labelers as registered with FDA. Repackagers relabel another company's product; share* is of listed packages, not sales.

LabelerTypePackagesStatus
Novo Nordiskunknown6SUPPLYING
A-S Medication Solutionsunknown2SUPPLYING
REMEDYREPACK INC.repackager2SUPPLYING

Regulatory & supply eventsFDA · US

Shortages, recalls, and registration changes attached to this drug concept.

  • Jul 21, 2025
    RESOLVEDShortage resolved: Insulin Aspart Protamine and Insulin Aspart Mix 70/30 Injectable Suspension (Novo Nordisk, Inc.)

    Insulin Aspart Protamine and Insulin Aspart Mix 70/30 Injectable Suspension — reported in shortage by Novo Nordisk, Inc.. Therapeutic category: Endocrinology/Metabolism.

  • Jul 21, 2025
    SHORTAGEDrug shortage: Insulin Aspart Protamine and Insulin Aspart Mix 70/30 Injectable Suspension (Novo Nordisk, Inc.)

    Insulin Aspart Protamine and Insulin Aspart Mix 70/30 Injectable Suspension — reported in shortage by Novo Nordisk, Inc.. Therapeutic category: Endocrinology/Metabolism.